|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,238.00 GBX | +1.56% |
|
-.--% | - |
| 01-08 | Indivior PLC Provides Earnings Guidance for the Full Year 2026 | CI |
| 01-08 | Indivior Expects Up to $1.20 Billion in 2026 Net Revenue | MT |
| Capitalization | 4.12B 3.5B 3.25B 3.03B 5.65B 378B 5.99B 37.09B 14.72B 179B 15.44B 15.12B 650B | P/E ratio 2025 * |
18.7x | P/E ratio 2026 * | 12.2x |
|---|---|---|---|---|---|
| Enterprise value | 4.17B 3.54B 3.28B 3.07B 5.72B 383B 6.06B 37.53B 14.9B 181B 15.62B 15.3B 657B | EV / Sales 2025 * |
3.5x | EV / Sales 2026 * | 3.33x |
| Free-Float |
96.11% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Indivior PLC
More recommendations
More press releases
More news
| 1 day | +1.56% | ||
| 6 months | +1.56% |
| 1 year | 598.5 |  | 1,264 |
| 3 years | 554.5 | | 1,993 |
| 5 years | 554.5 | | 2,020 |
| 10 years | 104.9 | | 2,523 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Ciaffoni
CEO | Chief Executive Officer | 55 | - |
Ryan Preblick
DFI | Director of Finance/CFO | 50 | 2020-06-28 |
| Compliance Officer | - | 2025-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Juliet Thompson
BRD | Director/Board Member | 59 | 2021-03-23 |
Mark Stejbach
BRD | Director/Board Member | 63 | 2021-03-23 |
Barbara Ryan
BRD | Director/Board Member | 66 | 2022-05-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.56% | -.--% | - | - | 4.12B | |
| -0.55% | -1.77% | -11.57% | -33.73% | 65.28B | |
| +1.59% | +3.16% | +15.53% | -7.93% | 8.78B | |
| -2.90% | -2.79% | +24.43% | +34.62% | 8.14B | |
| +3.61% | 0.00% | +10.76% | +67.92% | 6.44B | |
| +3.24% | +0.28% | -15.40% | +112.75% | 5.51B | |
| +3.10% | -1.25% | -11.47% | -19.93% | 2.97B | |
| -1.73% | -3.50% | +24.87% | +17.17% | 2.77B | |
| -4.86% | -4.76% | +48.65% | +36.38% | 2.64B | |
| Average | +0.34% | -0.77% | +10.73% | +25.91% | 12.82B | |
| Weighted average by Cap. | -0.06% | -0.97% | -2.65% | -8.26% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.19B 1.01B 939M 877M 1.64B 109B 1.73B 10.73B 4.26B 51.65B 4.46B 4.37B 188B | 1.14B 974M 902M 843M 1.57B 105B 1.67B 10.31B 4.09B 49.66B 4.29B 4.2B 181B |
| Net income | 225M 191M 177M 165M 308M 20.63B 327M 2.02B 803M 9.74B 842M 825M 35.43B | 349M 297M 275M 257M 479M 32.05B 508M 3.14B 1.25B 15.13B 1.31B 1.28B 55.05B |
| Net Debt | 49.64M 42.22M 39.13M 36.57M 68.17M 4.56B 72.26M 447M 178M 2.15B 186M 182M 7.83B | -299M -255M -236M -220M -411M -27.5B -436M -2.7B -1.07B -12.98B -1.12B -1.1B -47.23B |
More financial data
* Estimated data
Employees
1,041
Sector
Pharmaceuticals
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
32.97USD
Average target price
45.57USD
Spread / Average Target
+38.22%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- INDV Stock
- INDV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition